Gossamer Bio Faces Class Action Lawsuit Over Concealed Risks Following Troubling Phase 3 Trial Results#USA#Class_Action#San_Francisco#Gossamer_Bio#PROSERA_Trial
Gossamer Bio Faces Class Action Lawsuit Over Concealed Risks Following Troubling Phase 3 Trial Results
Gossamer Bio, Inc. is embroiled in a class action lawsuit after revealing the Phase 3 PROSERA trial results, affecting investor trust and stock price significantly.
third-news.com
May 30, 2026 at 2:08 PM
Gossamer Bio Faces Class Action Lawsuit Over Concealed Risks Following Troubling Phase 3 Trial Results#USA#Class_Action#San_Francisco#Gossamer_Bio#PROSERA_Trial
Investors Urged to Join Gossamer Bio Class Action Amid Fraud Allegations#United_States#New_York#Levi_&_Korsinsky#Gossamer_Bio#PROSERA_Trial
Investors Urged to Join Gossamer Bio Class Action Amid Fraud Allegations
Investors of Gossamer Bio Inc. may seek to lead a class action lawsuit following claims of undisclosed clinical trial failures that led to significant financial losses.
third-news.com
May 20, 2026 at 2:54 PM
Investors Urged to Join Gossamer Bio Class Action Amid Fraud Allegations#United_States#New_York#Levi_&_Korsinsky#Gossamer_Bio#PROSERA_Trial
Investors of Gossamer Bio Face Class Action as Allegations of Concealed Drug Risks Emerge#United_States#San_Francisco#Securities_Class_Action#Gossamer_Bio#PROSERA_Trial
Investors of Gossamer Bio Face Class Action as Allegations of Concealed Drug Risks Emerge
Gossamer Bio is under investigation, facing a lawsuit alleging it misled investors about the risks of a key drug trial that failed to meet expectations.
third-news.com
May 18, 2026 at 4:31 PM
Investors of Gossamer Bio Face Class Action as Allegations of Concealed Drug Risks Emerge#United_States#San_Francisco#Securities_Class_Action#Gossamer_Bio#PROSERA_Trial
Gossamer Bio Faces Class Action Lawsuit After Phase 3 Trial Failure and Significant Stock Drop#USA#San_Francisco#Securities_Class_Action#Gossamer_Bio#PROSERA_Trial
Gossamer Bio Faces Class Action Lawsuit After Phase 3 Trial Failure and Significant Stock Drop
A securities class action has been filed against Gossamer Bio after an 80% stock drop stemming from failures in their Phase 3 trial. Investors are encouraged to report losses.
third-news.com
April 17, 2026 at 12:27 PM
Gossamer Bio Faces Class Action Lawsuit After Phase 3 Trial Failure and Significant Stock Drop#USA#San_Francisco#Securities_Class_Action#Gossamer_Bio#PROSERA_Trial
Gossamer Bio Faces Major Setback as Phase 3 PROSERA Trial Results Fail to Meet Expectations#USA#New_York#Gossamer_Bio#seralutinib#PROSERA_Trial
Gossamer Bio Faces Major Setback as Phase 3 PROSERA Trial Results Fail to Meet Expectations
Gossamer Bio, Inc. suffers a significant drop in stock value following disappointing Phase 3 trials, raising concerns among investors and stakeholders.
third-news.com
April 1, 2026 at 2:13 PM
Gossamer Bio Faces Major Setback as Phase 3 PROSERA Trial Results Fail to Meet Expectations#USA#New_York#Gossamer_Bio#seralutinib#PROSERA_Trial